
While Novo Nordisk has taken the center stage of the obesity market in the US, the Danish pharmaceutical firm’s archrival there, Eli Lilly, is plotting ways to commercially challenge Wegovy with its own candidate, tirzepatide.
”Based on our current data, we look forward to going through the data with the FDA [US Food and Drug Administration, -ed.] to discuss the possibility of receiving an accelerated pathway in this indication,” said Dan Skovronsky, chief scientific and medical officer of Eli Lilly, during a teleconference for analysts and investors.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app